Comparison
Two long-ish GHRH-axis options: the approved drug with outcome data versus the week-long research analog.
Tesamorelin is FDA-approved with randomized visceral-fat trials behind a defined daily schedule; CJC-1295 DAC offers weekly convenience through albumin binding but has no outcome trials and a non-physiologic elevation pattern.
Tesamorelin, decisively: phase 3 randomized trials of visceral-fat reduction in HIV lipodystrophy and FDA approval. CJC-1295 DAC has early human pharmacology studies showing sustained GH and IGF-1 elevation: pharmacology, not outcomes.
Tesamorelin is daily and pulse-friendly, matching physiologic GHRH signaling. The DAC conjugate binds albumin and extends CJC-1295's half-life to roughly a week, which is convenient but produces sustained rather than pulsatile elevation: the community's pulse-versus-bleed debate.
Tesamorelin is prescription-only and counterfeited because of cost. CJC-1295 DAC is unapproved, appears in FDA compounding discussions, and is WADA-prohibited like all GH-releasing factors.
| Dimension | Tesamorelin | CJC-1295 DAC |
|---|---|---|
| Overall evidence grade | A | C |
| Evidence label | Strong human evidence | Limited human evidence |
| Regulatory status | Approved for specific use | Investigational / not approved |
| Editorial confidence | High confidence | Moderate confidence |
| Efficacy | 4/5 substantial | 2/5 limited |
| Safety | 3/5 emerging | 2/5 limited |
| Regulatory risk | 1/5 low | 5/5 very high |
| Product quality risk | 3/5 moderate | 5/5 very high |
| Primary claim categories | Approved HIV lipodystrophy context, Visceral adipose tissue evidence, Liver-fat research context, Growth hormone pathway claims, Product-quality and regulatory risks | Healthy-adult GH and IGF-1 pharmacology, DAC-specific identity, HIV visceral-obesity registry context, FDA compounding and product-quality risk, Eligibility and product-quality context |
Tesamorelin has controlled human data for reducing visceral abdominal fat in HIV lipodystrophy. People also discuss it for body composition, cutting, and anti-aging, but those uses sit inside the GH/IGF-1 risk profile and much weaker non-label evidence.
CJC-1295 DAC has DAC-specific investigational context: healthy-adult endocrine pharmacology, terminated registry context, regulatory review, and product-quality risk, not body-composition, anti-aging, recovery, or stack claims.
FDA. Egrifta (tesamorelin for injection) NDA approval letter 2010.
Accessed 2026-06-09.
FDA approval letter for Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
PMID:20554713 Accessed 2026-06-09.
Pooled phase 3 randomized placebo-controlled trial evidence in antiretroviral-treated people with HIV and excess abdominal fat.
doi:10.1210/jc.2005-1536 PMID:16352683 Accessed 2026-06-09.
Randomized placebo-controlled healthy-adult study reporting dose-dependent GH and IGF-1 increases after subcutaneous CJC-1295 with no serious adverse reactions in that study context.
FDA. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting 2024.
Accessed 2026-06-09.
FDA briefing distinguishes DAC and non-DAC CJC-1295 forms as separate active moieties, states none of the reviewed substances are components of FDA-approved drugs, and summarizes characterization and safety concerns.